China is sprucing up its pharma sector
The changes are helping multinational drugmakers. In time they may boost the domestic industry
CHINA is home to 1.4bn people. The population is ageing, and thus more vulnerable to ailments. Sustained economic growth is making the country richer, and more able to afford remedies. To foreign pharmaceutical firms, this looks like a winning combination. They are less keen on protracted review times, onerous rules and the reams of paperwork required to sell drugs in China. It can take a decade after approval in America for foreign drugs to reach Chinese patients.
This article appeared in the Business section of the print edition under the headline “Swallowing bitter pills”
Business September 1st 2018
- China is sprucing up its pharma sector
- Why Indian carriers are losing money
- YouTube is fighting for a slice of the premium-video market
- A disaster leaves a European infrastructure giant on edge
- Asset managers get involved in the companies they own
- BMW’s reputation in South Korea goes up in flames
- Disputes over goodwill can seem arcane
From the September 1st 2018 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Business
OpenAI’s latest model will change the economics of software
The more reasoning it does, the more computer power it uses
TikTok’s time is up. Can Donald Trump save it?
The imperilled app hopes for help from an old foe
The UFC, Dana White and the rise of bloodsport entertainment
There is more to the mixed-martial-arts impresario than his friendship with Donald Trump
Will Elon Musk scrap his plan to invest in a gigafactory in Mexico?
Donald Trump’s return to the White House may have changed Tesla’s plans
Germany is going nuts for Dubai chocolate
Will the hype last?
The year ahead: a message from the CEO
From the desk of Stew Pidd